Table 5

Apparent affinity of Asn-124 mutant receptors for antagonists

DrugKI
D2N124AN124LN124Q
nM
Epidepride +sodium0.08 (0.07–0.09)0.35 (0.29–0.42)5-a 0.26 (0.2–0.33)5-a 1.6 (1.2–2.0)5-a
− sodium1.6 (1.0–2.5)3.8 (2.6–5.5)3.0 (2.0–4.7)17 (12–25)5-a
Δsodium19111211
YM09151-2 +sodium0.03 (0.02–0.03)0.12 (0.10–0.14)5-a 0.11 (0.09–0.12)5-a 0.48 (0.37–0.62)5-a
− sodium0.22 (0.19–0.26)0.67 (0.59–0.76)5-a 0.63 (0.49–0.81)5-a 5.7 (5.0–6.4)5-a
Δsodium86612
Tropapride +sodium0.07 (0.06–0.08)0.28 (0.21–0.38)5-a 0.29 (0.23–0.36)5-a 2.2 (1.4–3.3)5-a
− sodium0.74 (0.34–1.6)1.4 (1.2–1.8)2.0 (1.6–2.5)19 (16–23)5-a
Δsodium11579
Sulpiride +sodium48 (47–50)139 (114–169)5-a 132 (116–150)5-a 454 (403–512)5-a
− sodium410 (360–480)1,310 (1,110–1,550)5-a 1,206 (962–1,510)5-a 8,525 (6,062–11,990)5-a
Δsodium95918
(+)-Butaclamol +sodium0.2 (0.1–0.2)0.8 (0.7–0.9)5-a 0.9 (0.7–1.0)5-a 2.8 (2.1–3.8)5-a
Haloperidol +sodium1.0 (0.9–1.2)0.6 (0.5–0.8)0.4 (0.3–0.5)5-a 5.0 (4.3–5.7)5-a
Clozapine +sodium72 (63–82)147 (128–170)5-a 84 (76–93)336 (321–351)5-a

Apparent affinity (K I) values for the indicated drugs were determined by inhibition of the binding of [3H]spiperone, as described under Experimental Procedures. Each value is the geometric mean of four to six independent experiments, followed in parentheses by the limits defined by the asymmetrical S.E. For the substituted benzamide derivates, the fold change in affinity resulting from the presence or absence of sodium (Δsodium) is also given.

    • 5-a  P < 0.05 compared with the affinity of D2L for that drug.